What's Happening?
Recent findings suggest that Veozah, a non-hormonal medication approved by the FDA for treating hot flashes, may also alleviate symptoms of anxiety and depression. The OPTION-VMS study, which is ongoing, has shown that women taking Veozah reported significant
improvements in these symptoms over a 12-week period. The study involved 656 women aged 40 to 75 who were experiencing hot flashes and were prescribed various medications, including Veozah. The results indicated that Veozah not only reduced hot flash symptoms but also improved mood-related symptoms. Experts like Dr. Mary Jane Minkin and Dr. Jessica Shepherd suggest that the drug's mechanism, which involves blocking neurokinin 3 receptors in the brain, might contribute to these additional benefits.
Why It's Important?
The discovery of Veozah's potential benefits beyond hot flash relief could lead to a more comprehensive approach to menopause care. This could be particularly beneficial for women experiencing new onset anxiety and depression during menopause. The findings suggest that future therapies might address interconnected brain pathways affecting multiple menopausal symptoms, rather than treating them as separate issues. This could improve the quality of life for many women and provide a new avenue for managing menopause-related mood disorders.
What's Next?
While the study's findings are promising, further research is needed to confirm Veozah's efficacy in treating anxiety and depression independently of hot flashes. Experts caution that Veozah should not replace traditional treatments like antidepressants or talk therapy but could be used as an additional therapy. The ongoing research may lead to new guidelines for menopause treatment, potentially influencing how healthcare providers address menopause-related mood disorders.
